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tially negative. On March 30, 2007, the patient underwent a
successful surgical repair, including descending thoracic aorta–left
renal artery (side-to-side anastomosis), and sequential right renal
artery (end-to-side anastomosis) using one limb of a No. 16
Hemashield (Boston Scientific, Natick, Mass) double-velour Da-
cron Y-graft. The other limb of the graft was extended down to the
left common iliac artery for end-to-side anastomosis (Fig 1).
During the surgery, the patient had multiple fibromatoses
in the intestine, measuring 2 mm and 20 mm in size. The patient
also had a neurofibromatosis lesion in the oral cavity, involving
the supraglottis, and a retropharyngeal region, without signifi-
cant respiratory problem or difficulty with swallowing.
Since reconstructive surgery, the patient has become normo-
tensive and completely asymptomatic from the lower extremity
ischemic symptoms. The patient had exertional dyspnea, which
was also completely dissipated.
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The authors are to be congratulated on their success with a case
of neurofibromatosis vasculopathy presenting with renovascular hy-
pertension, aortic and renal artery stenosis. Neurofibromatosis is
among the most common inherited human diseases. The cardinal
features of café au lait macules, neurofibromas, and iris hamartomas
are present in nearly all adult patients with the diagnosis of neurofi-
bromatosis type I. Vascular abnormalities have been increasingly
recognized as an uncommon complication of the disorder. Arterial
stenoses of the aorta, renal and mesenteric vessels are often long
segment and typically are not amenable to endovascular treatment.
In general, our approach is open reconstruction using aorto-
plasty or bypass, with or without reconstruction of the renal and
mesenteric arteries. Isolated renal or mesenteric stenosis may be
treated with angioplasty as a bridge to open reconstruction, but
one should expect high recurrence rates based on our recent review
of the literature.1 The dysplastic nature of the vasculopathy may
predispose patients to neointimal hyperplasia.
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Regarding “Patterns of in-stent restenosis after
carotid artery stenting: Classification and implications
for long term outcome”
With great interest we read the article by Lal et al,1 who found
that type of in-stent restenosis (ISR) and diabetes to be an indepen-
dent predictors of revascularization after carotid angioplasty and
stenting (CAS). Furthermore, the type of stent used for CAS was also
observed to influence the ISR pattern. ISR occurred more often in
patients treated with the Acculink stent (Abbott Vascular, Abbott
Park, Ill) compared with the Wallstent (Boston Scientific Corp,
Natick, Mass). However, neither in the Methods nor in Table II it is
clear how many stents of each type were used. It is therefore not
objectified if the observed phenomenon was an absolute or a relative
difference. We would like to make two remarks.
First, the incidence of ISR is highly dependent on the reste-
nosis definition and the duplex velocity criteria used. Assessment of
generally accepted duplex criteria for grading stenosis after carotid
endarterectomy has been shown to be not reliable after stenting.2,3
Although several stent types have been used in these studies,
surprisingly, a comparison for differences in duplex measurements
between stent types has not been performed.
In an animal experimental study (unpublished data), we eval-
uated velocity changes due to placement of two different carotid
stent types, the Wallstent vs Precise (Cordis, Miami Lakes, Fla).
Duplex velocities before and after stenting were measured at five
predetermined points. The Precise stent did not cause significant
higher velocities compared with baseline. However, the Wallstent
was responsible for significantly higher velocities, both in-stent and
directly after stenting, compared with the native artery.
We concluded that (1) placement of a stent in the carotid artery
can cause an increase in duplex velocities in the absence of residual or
true in-stent stenosis, (2) alterations are stent-type dependent and do
not justify a general approach to new velocity criteria indiscriminately
applied to all stents, and (3) vascular laboratories have to develop
Fig 1. This postoperativemagnetic resonance angiography shows
a functioning aorta–bilateral renal artery bypass and left common
iliac artery bypass graft.
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specific velocity criteria for the evaluation of patients after CAS. Also,
30-day complication rates may vary according to stent type, free cell
area, and cell design. Complication rates were highest for open cell
types and increased with larger free cell area.4
In summary, there is growing evidence that clinical outcome,
duplex velocities, and need for revascularization are all influenced by
type and design of stent. Second, there is currently no way to predict
which low-grade lesions will progress to high-grade or symptomatic
lesions, or both, which need intervention. Although Lal et al5 in a
previous report described that a higher incidence of residual stenosis
after CAS translates into a higher incidence of ISR during follow-up,
they failed to establish any correlation between restenosis formation
and the existence of residual lesions in their latest report.
The authors pursue a classification that offers an opportunity
for early identification of high-risk patients for monitoring and
treatment. The authors suggest that providing a standardized
method of describing restenotic lesions will facilitate further inves-
tigations into adjunctive treatments for ISR and improved stent
design. We propose that citation of stent type and residual lesions
become an essential component of this method.
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Reply
Thank you for your interest in our article relating patterns of
in-stent restenosis (ISR) after carotid artery stenting (CAS) to long-
term outcomes.1 As stated by you, the key findingwas that the type of
ISR and diabetes were key independent predictors of future high-
grade ISR necessitating revascularization after CAS. You have made
several remarks, and we appreciate the opportunity to clarify them.
As stated in the abstract and in the Results section, we found
differences in the pattern of ISR between the Acculink (Abbott
Vascular, Abbott Park, Ill) and Wallstent (Boston Scientific,
Natick, Mass) stents on univariate analysis. However, we did not
find a difference in the total incidence of ISR between the two
types of stents used. We refer you to page 837, first paragraph,
where we state, “In this cohort, 37 patients had been treated with
a Wallstent and 48 with an Acculink stent. The incidence of ISR
did not vary with the type of stent used or the type of lesion treated.
Univariate analysis indicated a difference in the patterns of ISR
between stent types. Intrastent ISR patterns (types 2 and 3)
occurred more frequently after placement of Acculink stents com-
pared with Wallstents (P  .03).”
We agree with you that the incidence of ISR is highly depen-
dent on the definition of restenosis and the duplex ultrasound
(DUS) velocity criteria used.We agree that in the past, doubts have
been raised regarding the accuracy of DUS in identifying ISR after
stenting. However, in 2004 we demonstrated that DUS remained
an accurate method of identifying residual ISR, provided the
velocity criteria were revised upwards.2 Furthermore, in an article
published in 2008,3 we clearly demonstrated that the relationship
between DUS velocities and stenosis within a stent is maintained
after CAS. However, the velocity criteria need to be revised up-
wards. In that article, we offered revised velocity criteria that
accurately identify low-, moderate-, and high-grade ISR after CAS.
We thank you for providing animal data demonstrating that
velocity profiles within a stent are increased despite normal luminal
diameters. This substantiates what we have demonstrated in our
patients in our recent studies.2,3 The differences you observed in
velocity profiles between the Wallstent and the Precise stent (Cor-
dis, Miami Lakes, Fla) are intriguing and substantiate what we have
also pointed out.3 On page 71, we stated that, “Because the
observed velocity alterations appear to result from altered stent-
artery biomechanics, it is possible that future alterations in stent
composition and design, with consequent changes in the mechan-
ical properties, may result in altered velocity profiles.”
The current study1 was prompted by the very thought ex-
pressed in your letter that there is currently no way to predict which
low-grade lesions will progress to high-grade or symptomatic
lesions that need reintervention. Our results provide evidence that
diffuse proliferative (type IV) ISR lesions and diabetes are impor-
tant and independent predictors of which low-grade lesions will
progress to high-grade lesions that will need reintervention.
The prior article by our group2 did not describe that a high
incidence of residual stenosis after CAS translates into a higher
incidence of ISR during follow-up. You may have misinterpreted
the study. The focus of that article was to investigate whether DUS
velocity criteria need to be revised after CAS. As previously stated,
our answer was in the affirmative, and we offered revised velocity
criteria to identify residual stenosis after CAS. The current article
again did not focus on that question, and in any case, we did not
identify any patients with residual lesions after CAS.
In conclusion, our group has been extremely interested in
arterial stent biomechanics and how they relate to the phenomena
of ISR. Our series of articles1-4 have allowed us to conclude that:
1. ISR is not an infrequent occurrence after CAS.
2. DUS testing remains accurate in identifying ISR; however, the
velocity criteria need to be revised upwards.
3. We have established and published the revised velocity criteria
to identify residual, moderate, and high-grade ISR after CAS.
4. Our results indicate that presence of diabetes and type IV
patterns of ISR can predict which low-grade lesions will
progress to high-grade lesions necessitating reintervention.
Thank you.
Brajesh K. Lal, MD
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